<DOC>
	<DOCNO>NCT01739868</DOCNO>
	<brief_summary>The main objective study understand pathophysiological mechanism involve switch pre-diabetes type 2 diabetes identify new biomarkers type 2 diabetes risk population patient pre-diabetes .</brief_summary>
	<brief_title>Screening Understanding Pre-diabetes : DECODIAB</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Adult patient ( ≥18 year ) Subjects diabetes risk score ≥ 12 impaired fast glucose : blood glucose ≥ 1.10 g/l &lt; 1 .26 g/L And impaired fasting glucose : blood glucose ≥ 1.10 g/l &lt; 1 .26 g/L ; blood glucose ≥ 1g/l &lt; 1,1 g/L WITH HbA1C ≥ 6,5 % Signed informed consent Subjects affiliate appropriate social security system Fasting glycemia ≥ 1.26 g/l Fasting glycemia ≤ 1.10 g/l AND HbA1C &lt; 6,5 % Fasting glycemia &lt; 1 g/l Subjects previously treat oral antidiabetic : metformin , glitazones , inhibitor αglucosidase , sulfonylurea , repaglinide , inhibitor DPPIV . Subjects previously treat insulin , except gestational diabetes Severe coagulation disorder Thrombocytopenia &lt; 100 000/mm 3 Severe psychiatric disorder Severe renal insufficiency ( creatinine clearance &lt; 30 ml/min ) Severe hepatic insufficiency Alcohol abuse ( &gt; 30g/j ) Contraindication realization local anesthetic Subject unable follow study 5 year followup Subject exclusion period previous study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pre-diabetes</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Diabetes risk score</keyword>
</DOC>